Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of nonhuman primate

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14049-

  Sebastian, Waldy San ^a   Kells, Adrian P ^a   Bringas, John ^a   Samaranch, Lluis ^a   Hadaczek, Piotr ^a   Ciesielska, Agnieszka ^a   Macayan, Michael J ^a   Pivirotto, Phillip J ^a   Forsayeth, John ^a   Osborne, Sheryl ^b   Wright, J Fraser ^c,d   Green, Foad ^a   Heller, Gregory ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Children's Hospital of Philadelphia ^*

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; MONOAMINE;

ADENO ASSOCIATED VIRUS 2; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; MACACA FASCICULARIS; MESENCEPHALON; METABOLITE; MOTOR PERFORMANCE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; THREE DIMENSIONAL IMAGING; TISSUE SECTION; VENTRAL TEGMENTUM; VOLUME OF DISTRIBUTION;

EID: 84962949013     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.49     Document Type: Article

References (33)

1. 1 Lee, HF, Tsai, CR, Chi, CS, Chang, TM, Lee, HJ, Aromatic L-amino acid decarboxylase deficiency in Taiwan. Eur J Paediatr Neurol 13 (2009), 135–140.
2. 2 Manegold, C, Hoffmann, GF, Degen, I, Ikonomidou, H, Knust, A, Laass, MW, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis 32 (2009), 371–380.
3. 3 Hyland, K, Clayton, PT, Aromatic amino acid decarboxylase deficiency in twins. J Inherit Metab Dis 13 (1990), 301–304.
4. 4 Brun, L, Ngu, LH, Keng, WT, Ch'ng, GS, Choy, YS, Hwu, WL, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 75 (2010), 64–71.
5. 5 Hoffmann, GF, Assmann, B, Bräutigam, C, Dionisi-Vici, C, Häussler, M, de Klerk, JB, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol 54:suppl. 6 (2003), S56–S65.
6. 6 Yahr, MD, Duvoisin, RC, Schear, MJ, Barrett, RE, Hoehn, MM, Treatment of parkinsonism with levodopa. Arch Neurol 21 (1969), 343–354.
7. 7 Christine, CW, Starr, PA, Larson, PS, Eberling, JL, Jagust, WJ, Hawkins, RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73 (2009), 1662–1669.
8. 8 Muramatsu, S, Fujimoto, K, Kato, S, Mizukami, H, Asari, S, Ikeguchi, K, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18 (2010), 1731–1735.
9. 9 Hwu, WL, Muramatsu, S, Tseng, SH, Tzen, KY, Lee, NC, Chien, YH, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med, 4, 2012, 134ra61.
10. 10 Johnston, LC, Eberling, J, Pivirotto, P, Hadaczek, P, Federoff, HJ, Forsayeth, J, et al. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 20 (2009), 497–510.
11. 11 Kells, AP, Forsayeth, J, Bankiewicz, KS, Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis 48 (2012), 228–235.
12. 12 Ciesielska, A, Mittermeyer, G, Hadaczek, P, Kells, AP, Forsayeth, J, Bankiewicz, KS, Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther 19 (2011), 922–927.
13. 13 Richardson, RM, Gimenez, F, Salegio, EA, Su, X, Bringas, J, Berger, MS, et al. T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery. Neurosurgery 69 (2011), 154–163 discussion 163.
14. 14 Richardson, RM, Kells, AP, Martin, AJ, Larson, PS, Starr, PA, Piferi, PG, et al. Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg 89 (2011), 141–151.
15. 15 San Sebastian, W, Richardson, RM, Kells, AP, Lamarre, C, Bringas, J, Pivirotto, P, et al. Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther 23 (2012), 210–217.
16. 16 Bankiewicz, KS, Forsayeth, J, Eberling, JL, Sanchez-Pernaute, R, Pivirotto, P, Bringas, J, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14 (2006), 564–570.
17. 17 Forsayeth, JR, Eberling, JL, Sanftner, LM, Zhen, Z, Pivirotto, P, Bringas, J, et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther 14 (2006), 571–577.
18. 18 Hadaczek, P, Eberling, JL, Pivirotto, P, Bringas, J, Forsayeth, J, Bankiewicz, KS, Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 18 (2010), 1458–1461.
19. 19 Daadi, MM, Pivirotto, P, Bringas, J, Cunningham, J, Forsayeth, J, Eberling, J, et al. Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys. Neuroreport 17 (2006), 201–204.
20. 20 Eberling, JL, Jagust, WJ, Christine, CW, Starr, P, Larson, P, Bankiewicz, KS, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70 (2008), 1980–1983.
21. 21 Mittermeyer, G, Christine, CW, Rosenbluth, KH, Baker, SL, Starr, P, Larson, P, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 23 (2012), 377–381.
22. 22 Dahlstroem, A, Fuxe, K, Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand Suppl 232 (1964), 231–255.
23. 23 Ciesielska, A, Hadaczek, P, Mittermeyer, G, Zhou, S, Wright, JF, Bankiewicz, KS, et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther 21 (2013), 158–166.
24. 24 Yin, D, Valles, FE, Fiandaca, MS, Forsayeth, J, Larson, P, Starr, P, et al. Striatal volume differences between non-human and human primates. J Neurosci Methods 176 (2009), 200–205.
25. 25 Hyland, K, Surtees, RA, Rodeck, C, Clayton, PT, Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 42 (1992), 1980–1988.
26. 26 Sanftner, LM, Suzuki, BM, Doroudchi, MM, Feng, L, McClelland, A, Forsayeth, JR, et al. Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol Ther 9 (2004), 403–409.
27. 27 Calcedo, R, Vandenberghe, LH, Gao, G, Lin, J, Wilson, JM, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199 (2009), 381–390.
28. 28 Wright, JF, Wellman, J, High, KA, Manufacturing and regulatory strategies for clinical AAV2-hRPE65. Curr Gene Ther 10 (2010), 341–349.
29. 29 Krauze, MT, Saito, R, Noble, C, Tamas, M, Bringas, J, Park, JW, et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 103 (2005), 923–929.
30. 30 Fiandaca, MS, Forsayeth, JR, Dickinson, PJ, Bankiewicz, KS, Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 5 (2008), 123–127.
31. 31 Rosenbluth, KH, Gimenez, F, Kells, AP, Salegio, EA, Mittermeyer, GM, Modera, K, et al. Automated segmentation tool for brain infusions. PLoS ONE, 8, 2013, e64452.
32. 32 Cunningham, J, Pivirotto, P, Bringas, J, Suzuki, B, Vijay, S, Sanftner, L, et al. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther 16 (2008), 1267–1275.
33. 33 Schneider, CA, Rasband, WS, Eliceiri, KW, NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9 (2012), 671–675.